The Novus antibody lab has been very busy over the past two weeks. Not only has Novus marketed four new antibodies this past week, but the laboratory technicians have purified numerous antibodies, tested new antibody lots in Western blot as a part of Novus' stringent QC analysis process, as well as custom conjugating various antibodies.
One of Novus' newly released antibodies, a rabbit polyclonal anti-CLOCK antibody (catalog number NBP1-30326), is perfectly suited for the study of circadian rhythm. The CLOCK protein, also known as KAT13D, belongs to the basic helix-loop-helix (bHLH) family of transcription factors. It is a major protein of interest in the study of circadian rhythm as polymorphisms within the encoded protein have been shown to be associated with abnormal circadian rhythm behavior, such as sleep disorders. This new CLOCK antibody complements Novus' full line of circadian rhythm antibodies, including BMAL1 antibodies, PER1 and PER2 antibodies, Timeless antibodies and Cryptochrome antibodies.
As a leading supplier of HIF antibodies, Novus is continually monitoring scientific trends for the latest HIF and hypoxia related research reagents. Two out of Novus' four recently launched antibodies are HIF related. One of particular interest is a new mouse monoclonal anti-Factor Inhibiting HIF-1 antibody (clone 162C) (catalog number NBP1-30333). The Factor Inhibiting HIF-1 protein (Entrez GeneID 55662) facilitates repression of HIF-1 transcriptional activity by binding to von Hippel-Lindau (VHL), which acts as a transcriptional corepressor. VHL inhibits HIF-1 alpha transactivation function by recruiting histone deacetylases. Involvement of VHL in association with FIH provides a unifying mechanism for the modulation of HIF-1 alpha protein stabilization and transcriptional activation in response to changes in cellular oxygen concentration. The second new HIF related antibody is a mouse monoclonal anti-HIF Prolyl Hydroxylase 2 antibody (clone 366G/76/3) (catalog number NBP1-30328). The HIF Prolyl Hydroxylase 2 protein is a HIF-alpha modifier that hydroxylates HIF-1 alpha at Pro(402) and Pro(564), and HIF-2 alpha. It targets HIF through the hydroxylation for proteasomal degradation via the von Hippel-Lindau ubiquitylation complex. Novus also provides the research community with an extensive line of anti-VHL antibodies, which are frequently purchased in tandem with HIF target antibodies.
Lastly, Novus' fourth new antibody released this week is an anti-LOX propeptide antibody (catalog number NBP1-30327), often referred to as LOPP. This affinity purified rabbit polyclonal antibody recognizes the glycosylated propeptide form of the protein at approximately 35 kDa, as well as the proenzyme form at approximately 50 kDa. Novus' lab technicians thoroughly tested for the presence of these two forms by running this antibody in Western blot on MDA-MB-231 cell lysates.
